Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.

Autor: Yadav U; Division of Hematology, Mayo Clinic, Rochester, MN., Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN., Baughn LB; Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN., Greipp P; Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Ketterling R; Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Jevremovic D; Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Buadi FK; Division of Hematology, Mayo Clinic, Rochester, MN., Dingli D; Division of Hematology, Mayo Clinic, Rochester, MN., Lacy MQ; Division of Hematology, Mayo Clinic, Rochester, MN., Fonseca R; Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ., Bergsagel PL; Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ., Ailawadhi S; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL., Roy V; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL., Parrondo R; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL., Sher T; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL., Hayman SR; Division of Hematology, Mayo Clinic, Rochester, MN., Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN., Leung N; Division of Hematology, Mayo Clinic, Rochester, MN.; Division of Nephrology, Mayo Clinic, Rochester, MN., Cook J; Division of Hematology, Mayo Clinic, Rochester, MN., Binder M; Division of Hematology, Mayo Clinic, Rochester, MN., Muchtar E; Division of Hematology, Mayo Clinic, Rochester, MN., Warsame R; Division of Hematology, Mayo Clinic, Rochester, MN., Kourelis TV; Division of Hematology, Mayo Clinic, Rochester, MN., Go RS; Division of Hematology, Mayo Clinic, Rochester, MN., Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN., Seth A; Division of Hematology, Mayo Clinic, Rochester, MN., Lester SC; Department of Radiation Oncology, Mayo Clinic, Rochester, MN., Breen WG; Department of Radiation Oncology, Mayo Clinic, Rochester, MN., Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN., Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN., Gonsalves WI; Division of Hematology, Mayo Clinic, Rochester, MN.

Publikováno v: Blood [Blood] 2023 Nov 30; Vol. 142 (22), pp. 1871-1878.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.

Autor: Ganzel C; Hematology Department, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University of Jerusalem, Israel. Electronic address: ganzelc@szmc.org.il., Sun Z; Dana-Farber Cancer Institute, Boston, MA, USA., Baslan T; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Zhang Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gönen M; Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Abdel-Wahab OI; Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Racevskis J; Department of Oncology, Montefiore Medical Center, Bronx, NY, USA., Garrett-Bakelman F; Department of Medicine, Weill Cornell Medicine, New York, NY, USA; Departments of Medicine and Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, USA; University of Virginia Cancer Center, Charlottesville, VA, USA., Lowe SW; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA., Fernandez HF; Malignant Hematology and Cellular Therapy, Moffitt Cancer Center, Tampa, FL, USA., Ketterling R; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Luger SM; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Litzow M; Department of Medicine, Mayo Clinic, Rochester, MN, USA., Lazarus HM; Case Western Reserve, Cleveland, OH, USA., Rowe JM; Hematology Department, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University of Jerusalem, Israel., Tallman MS; Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Levine RL; Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Paietta E; Department of Oncology, Montefiore Medical Center, Bronx, NY, USA.

Publikováno v: Leukemia research [Leuk Res] 2022 Dec; Vol. 123, pp. 106971. Date of Electronic Publication: 2022 Oct 21.

Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML.

Autor: Xie Z; Mayo Clinic, Hematology Division, Rochester, MN, USA., Campestri G; Mayo Clinic, Hematology Division, Rochester, MN, USA., Lasho T; Mayo Clinic, Hematology Division, Rochester, MN, USA., Finke C; Mayo Clinic, Hematology Division, Rochester, MN, USA., Li M; Mayo Clinic, Department of Internal Medicine, Rochester, MN, USA., Binder M; Mayo Clinic, Hematology Division, Rochester, MN, USA., Fernandez J; Mayo Clinic, Hematology Division, Rochester, MN, USA., Olteanu H; Mayo Clinic, Department of Hematopathology, Rochester, MN, USA., Reichard KK; Mayo Clinic, Department of Hematopathology, Rochester, MN, USA., Ketterling R; Mayo Clinic, Department of Cytogenetics Laboratory, Rochester, MN, USA., Litzow M; Mayo Clinic, Hematology Division, Rochester, MN, USA., Tefferi A; Mayo Clinic, Hematology Division, Rochester, MN, USA., Mangaonkar A; Mayo Clinic, Hematology Division, Rochester, MN, USA., Gangat N; Mayo Clinic, Hematology Division, Rochester, MN, USA., Al-Kali A; Mayo Clinic, Hematology Division, Rochester, MN, USA., Patnaik MM; Mayo Clinic, Hematology Division, Rochester, MN, USA. Electronic address: patnaik.mrinal@mayo.edu.

Publikováno v: Leukemia research [Leuk Res] 2022 May; Vol. 116, pp. 106818. Date of Electronic Publication: 2022 Feb 22.

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups

Autor: Lrrzow, MR, Buck, G, Dewald, G, Fielding, A, Ketterling, R, Lazarus, HM, Luger, S, Marks, DI, McMillan, A, Moorman, AV, Paietta, E, Richards, SM, Rowe, JM, Tallman, MS, Goldstone, AH

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::e2380182fcfadc96cd9c1248e2694d25
https://ora.ox.ac.uk/objects/uuid:6d4b4a2e-eb3e-4b57-a94f-da0eb9a23294